Polycythemia vera is a type of blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. The most common treatment for polychythemia vera is having frequent blood withdrawals, using a needle in a vein (phlebotomy).
Major players operating in the global polycythemia vera therapeutics market include, ANP Technologies, Inc., Bristol-Myers Squibb Company, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxosmithKline plc, Galena Biopharma, Karus Therapeutics Limited, Miragen Therapeutics, Inc., Mylan N.V., Novartis AG, Pfizer Inc., PharmaEssentia Corporation, Teva Pharmaceuticals Industries Ltd.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Key Market Drivers:
High prevalence of blood cancer is expected to propel growth of the global polycythemia vera therapeutics market over the forecast period. For instance, according to the World Health Organization, India recorded 42055 new cases and 32,471 deaths due to leukemia in 2018.
Covid-19 Impact Analysis
Globally, as of 5:13pm CET, 10 February 2022, there have been 402,044,502 confirmed cases of COVID-19, including 5,770,023 deaths, reported to WHO. As of 6 February 2022, a total of 10,095,615,243 vaccine doses have been administered. Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals.
R&D of new therapies is expected to propel growth of the global polycythemia vera therapeutics market over the forecast period. For instance, in December 2021, Protagonist Therapeutics presented updated data from two Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients.
Major players operating in the global polycythemia vera therapeutics market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2021, the U.S Food and Drug Administration approved PharmaEssentia Corporation’s monopegylated, long-acting interferon ropeginterferon a-2b-njft (Besremi) for the treatment of patients with polycythemia vera.
Ask for PDF Brochure @
Reasons to Buy this Polycythemia Vera Therapeutics Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Polycythemia Vera Therapeutics market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Polycythemia Vera Therapeutics market
➡Leading company profiles reveal details of key Polycythemia Vera Therapeutics market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Polycythemia Vera Therapeutics market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Polycythemia Vera Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Polycythemia Vera Therapeutics Industry Impact
Chapter 2 Global Polycythemia Vera Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Polycythemia Vera Therapeutics (Volume and Value) by Type
2.3 Global Polycythemia Vera Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Polycythemia Vera Therapeutics Sales, Consumption, Export, Import by Regions
Chapter 5 North America Polycythemia Vera Therapeutics Market Analysis
Chapter 6 East Asia Polycythemia Vera Therapeutics Market Analysis
Chapter 7 Europe Polycythemia Vera Therapeutics Market Analysis
Chapter 8 South Asia Polycythemia Vera Therapeutics Market Analysis
Chapter 9 Southeast Asia Polycythemia Vera Therapeutics Market Analysis
Chapter 10 Middle East Polycythemia Vera Therapeutics Market Analysis
Chapter 11 Africa Polycythemia Vera Therapeutics Market Analysis
Chapter 12 Oceania Polycythemia Vera Therapeutics Market Analysis
Chapter 13 South America Polycythemia Vera Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Polycythemia Vera Therapeutics Business
Chapter 15 Global Polycythemia Vera Therapeutics Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027